Korn EL - Search Results

1

Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?

Rubinstein LV, Dancey JE, Korn EL, Smith MA, Wright JJ. Rubinstein LV, et al. Among authors: korn el. J Natl Cancer Inst. 2007 Oct 3;99(19):1422-3. doi: 10.1093/jnci/djm167. Epub 2007 Sep 25. J Natl Cancer Inst. 2007. PMID: 17895470 No abstract available.

2

Multinomial phase II trial designs.

Freidlin B, Dancey J, Korn EL, Zee B, Eisenhauer E. Freidlin B, et al. Among authors: korn el. J Clin Oncol. 2002 Jan 15;20(2):599. J Clin Oncol. 2002. PMID: 11786592 No abstract available.

3

Dose escalation trial designs based on a molecularly targeted endpoint.

Hunsberger S, Rubinstein LV, Dancey J, Korn EL. Hunsberger S, et al. Among authors: korn el. Stat Med. 2005 Jul 30;24(14):2171-81. doi: 10.1002/sim.2102. Stat Med. 2005. PMID: 15909289

4

Design issues of randomized phase II trials and a proposal for phase II screening trials.

Rubinstein LV, Korn EL, Freidlin B, Hunsberger S, Ivy SP, Smith MA. Rubinstein LV, et al. Among authors: korn el. J Clin Oncol. 2005 Oct 1;23(28):7199-206. doi: 10.1200/JCO.2005.01.149. J Clin Oncol. 2005. PMID: 16192604

5

Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?

Dodd LE, Korn EL, Freidlin B, Jaffe CC, Rubinstein LV, Dancey J, Mooney MM. Dodd LE, et al. Among authors: korn el. J Clin Oncol. 2008 Aug 1;26(22):3791-6. doi: 10.1200/JCO.2008.16.1711. J Clin Oncol. 2008. PMID: 18669467 Free PMC article. Review.

6

A comparison of two phase I trial designs.

Korn EL, Midthune D, Chen TT, Rubinstein LV, Christian MC, Simon RM. Korn EL, et al. Stat Med. 1994 Sep 30;13(18):1799-806. doi: 10.1002/sim.4780131802. Stat Med. 1994. PMID: 7997713

7

Comments on 'maintaining confidentiality of interim data to enhance trial integrity and credibility' by TR Fleming et al.

Korn EL, Hunsberger S, Freidlin B, Smith MA, Abrams JS. Korn EL, et al. Clin Trials. 2008;5(4):364-5; author reply 365-6. doi: 10.1177/1740774508094749. Clin Trials. 2008. PMID: 18697851 No abstract available.

8

Preliminary data release for randomized clinical trials of noninferiority: a new proposal.

Korn EL, Hunsberger S, Freidlin B, Smith MA, Abrams JS. Korn EL, et al. J Clin Oncol. 2005 Aug 20;23(24):5831-6. doi: 10.1200/JCO.2005.02.105. Epub 2005 Jul 18. J Clin Oncol. 2005. PMID: 16027441

9

Role of independent data-monitoring committees in randomized clinical trials sponsored by the National Cancer Institute.

Smith MA, Ungerleider RS, Korn EL, Rubinstein L, Simon R. Smith MA, et al. Among authors: korn el. J Clin Oncol. 1997 Jul;15(7):2736-43. doi: 10.1200/JCO.1997.15.7.2736. J Clin Oncol. 1997. PMID: 9215848

10

Evaluation of the contribution of randomised cancer clinical trials evaluating agents without documented single-agent activity.

Foster J, Freidlin B, Korn EL, Smith M. Foster J, et al. Among authors: korn el. ESMO Open. 2020 Oct;5(5):e000871. doi: 10.1136/esmoopen-2020-000871. ESMO Open. 2020. PMID: 33122353 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

226 results

Search Page

Filters